[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"addiction-nicotine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:addiction-nicotine":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615459","phase-2-accelerated-dtms-smoking-cessation-100615459",false,"NCT07292883","Accelerated dTMS Smoking Cessation","Accelerated Deep Transcranial Magnetic Stimulation for Smoking Cessation","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Tobacco use disorder as assessed by DSM-5;\n3. Fagerstrom Test of Nicotine Dependence (FTND) ≥ 4;\n4. Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of ≥ 7;\n5. Must sign and date the informed consent form;\n6. Stated willingness to comply with all study procedures.\n7. Able to communicate in English.\n\nExclusion Criteria:\n\n1. Reported smoking abstinence in the 3 months preceding screening visit;\n2. Current use of other smoking cessation aids;\n3. Contraindication to rTMS;\n4. Pregnancy, trying to become pregnant or breastfeeding;\n5. Current or recent history of cerebrovascular disease;\n6. Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the study at PI (or its delegate) discretion;\n7. Serious current or personal history of medical condition\u002Fdisease (neurological disorders, brain lesions, multiple sclerosis, head trauma, loss of consciousness, hearing loss, etc.) preventing same inclusion as per PI (or its delegate) discretion;\n8. Current, personal history or family history of seizures;\n9. Concomitant use of medication that lowers seizure threshold, such as clozapine;\n10. Concomitant use of more than 2 mg lorazepam (or an equivalent) or any anticonvulsants.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to examine whether a 5-day course of bilateral accelerated deep transcranial magnetic stimulation (aTMS) is a feasible treatment to help adults (18-65) with Tobacco Use Disorder to quit smoking. This study aims to enroll 30-40 participants and will examine treatment tolerability, treatment acceptability, participant retention, and adherence to scheduled treatment sessions.\n\nThere are two key objectives and hypotheses:\n\nObjective 1: To evaluate whether a 1-week course of bilateral aTMS (4 sessions per day for 5 days) is feasible and tolerable as a smoking cessation treatment.\n\nHypothesis 1: Feasibility will be demonstrated by acceptable tolerability, acceptability, retention, and adherence, with a practical target of 30 out of 40 participants completing the treatment.\n\nObjective 2: To explore how aTMS affects smoking outcomes, including:\n\n* Point-prevalence abstinence at end of treatment and at Weeks 3, 5, and 9.\n* Prolonged\u002Fcontinuous abstinence at Weeks 13 and 26.\n* Craving, cigarettes per day, and dependence severity. Hypothesis 2: Participants will show improvements on these outcomes from post-treatment through follow-up.",[26,27],"Tobacco Use Disorder","Addiction Nicotine",[29,30,31,32],"addiction","smoking cessation","Transcranial Magnetic Stimulation","Accelerated Repetitive Transcranial Magnetic Stimulation","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-21","ACTUAL",{"date":39,"type":37},"2026-02-24",{"date":41,"type":20},"2028-01-01",{"name":43,"class":44},"Waypoint Centre for Mental Health Care","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100617731","phase-2-the-conquer-trial---cessation-of-nicotine-quitting-with-e-cigarette-reduction-100617731","NCT07322432","The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction","The CONQUER Trial: Cessation Of Nicotine, QUitting With E-cigarette Reduction - A Single-Arm, Open-Label Clinical Trial to Assess the Efficacy of VapeAway in Promoting Vaping Cessation Compared to Historical Rates of Vaping Cessation","CONQUER","Inclusion Criteria:\n\n* Age: Adults aged 21 years and older\n* Current Vaping Behavior: Daily or near-daily use (≥5 days\u002Fweek or at least 20 days per month) of nicotine-containing e-cigarettes for at least the past 3 months.\n* Motivation and desire to quit as determined by all of the following three assessment tools:\n\n  * Score of 4 or 5 on all 5-point Likert-type scale questions (see appendix)\n  * Score of 6 or 7 on Motivation To Stop Scale (MTSS) (see appendix)\n  * Participants must be classified in the Preparation stage of the Transtheoretical Model of behavior change (see appendix)\n* Saliva Cotinine level ≥ 10 ng\u002Fml\n* Penn State Electronic Cigarette Dependence Index (PSECDI) of at least 4 and above\n* Willingness to participate in the study and all study requirements\n* Willingness to not use any other nicotine-containing products for the duration of the study\n* Ability to attend visits and provide informed consent\n\nExclusion Criteria:\n\n* Mental Health Concerns with a score above the following thresholds:\n\n  * PHQ-2 score ≥ 2 (see appendix)\n  * GAD-2 score ≥ 2 (see appendix)\n* Use of Other Tobacco or Nicotine Products:\n\n  * Use of any nicotine products except for vaping, including combustible tobacco (e.g., cigarettes) or other non-e-cigarette nicotine delivery systems within the past 30-days\n* Current Substance or alcohol Use Disorder:\n\n  * Self-reported or medically diagnosed substance use disorder (excluding nicotine), unless in sustained remission (\\>12 months).\n  * Illicit drug use in the past 60 days\n  * Screening positive for alcohol use disorder in past year\n* Medical Contraindications:\n\n  * Any serious medical condition or medication that would contraindicate participation in a behavioral cessation trial (to be defined and assessed by study physician or PI).\n  * Pregnant or breastfeeding\n  * Symptomatic cardiovascular disease\n  * Participation in another smoking\u002Fvaping cessation trial","21 Years",{"count":56,"type":20},70,[23],"This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy and safety of the investigational VapeAway system, a multi-component behavioral and nicotine-reduction intervention, for promoting cessation of nicotine-containing e-cigarette use in motivated adults. The primary objective is to determine if the VapeAway program can achieve a Continuous Abstinence Rate (CAR) of at least 25% at 30 days post-intervention completion, a rate which will be statistically compared to the historical spontaneous cessation rate of approximately 7%. Secondary objectives include assessing reductions in biochemical nicotine exposure (cotinine), vaping frequency, withdrawal symptoms, and electronic cigarette dependence, as well as characterizing the safety and tolerability profile of the intervention.\n\nParticipants will be asked to follow the VapeAway system (filters, Fix Bar and timeout periods) as prescribed by the protocol for about 42 days. During this time, participants should keep track of vaping sessions throughout the trial.",[27],[61,62,63,64],"Vaping","Vaping Addiction","Vaping Cessation","Vape","2026-01-05",{"date":67,"type":37},"2026-01-07",{"date":69,"type":37},"2025-12-24",{"date":71,"type":20},"2026-12",{"name":73,"class":74},"VapeAway","INDUSTRY",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":75},"100478070","predictive-and-impact-of-pain-after-6-months-of-radiotherapy-in-head-and-neck-cancer-100478070","NCT05505188","Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer","Predictive and Impact of Pain at 6 Months in Patients Treated With Radiotherapy for Head and Neck Cancer","DIP-CAOS","Inclusion Criteria:\n\n* Patients with a first Head and neck cancer whose therapeutic sequence involves radiotherapy\n* Patient over 18 years of age\n* Having given written consent\n* patient not previously treated with radiotherapy\n* Life expectancy \\> 3 months\n* World Health Organization (WHO) score \\\u003C 3\n* Histologically proven Head and Neck cancer\n* Stable patient, with no signs of recurrence or other progressive neoplasia at the time of the examination\n* Patient treated with radiotherapy\n* Patient fluent in French\n\nExclusion Criteria:\n\n* Non-consenting patient\n* History of malignancy, other than treated and cured basal cell or cervical cancer\n* Patient who has had a salvage surgery other than lymph node removal\n* Patient with evidence of recurrence or other progressive neoplasia at the time of examination\n* Patient who has had previous mutilating surgery (causing sequelae of swallowing and eating)\n* Uncontrolled infectious pathology\n* Patient under 18 years of age\n* Patient who is not fluent in French\n* Patient with a psychiatric pathology that could disrupt the study or prevent the interpretation of the results.",{"count":85,"type":20},120,[87],"NA","Head and neck cancers are a source of complications and after-effects related to the disease and treatment. These cancers and their treatment alter the quality of life of patients and generate pain with physical and psychological components. Chronic pain affects 36% of patients at 6 months and 30% after this period. These pains are responsible for the consumption of level II and III analgesics in 53% of these patients. At the same time, after the end of treatment, nearly a quarter of patients continued to smoke and half still consumed alcohol at least twice a week.\n\nThe hypothesis of this research is to investigate the correlation between pain and the continuation of addictions, the occurrence of depressive states, asthenia and the alteration of the patients' global quality of life.\n\nThe investigators propose a two-center prospective cohort study to evaluate this hypothesis at 6 months after radiotherapy treatment.\n\nThis study is planned to include 120 patients with a first head and neck cancer whit radiotherapy as part of their treatment sequence. The expected duration of inclusion is 18 months.\n\nThe identification of factors affecting survival, quality of life and patient compliance is essential to determine appropriate management, particularly by creating appropriate therapeutic education programs.",[90,91,92,93,94,95,96,27],"Neuropathic Pain","Anxiety Disorder\u002FAnxiety State","Pain, Chronic","Alcohol Use Disorder","Psychoactive Substance Use","Sleep","Symptoms and Signs",[98,99,100,101,102],"Head and neck cancer","pain","Quality of life","Addiction","Depression","2025-07-22",{"date":105,"type":37},"2025-07-25",{"date":107,"type":37},"2023-03-13",{"date":109,"type":20},"2026-09-01",{"name":111,"class":44},"University Hospital, Caen"]